These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32474203)

  • 41. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco.
    Yang J; Kim HY; Park S; Sentissi I; Green N; Oh BK; Kim Y; Oh KH; Paek E; Park YJ; Oh IH; Lee SH
    PLoS One; 2022; 17(4):e0267292. PubMed ID: 35439273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost-effectiveness of DOTS in urban Brazil.
    Mohan CI; Bishai D; Cavalcante S; Chaisson RE
    Int J Tuberc Lung Dis; 2007 Jan; 11(1):27-32. PubMed ID: 17217126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis.
    Diel R; Wrighton-Smith P; Zellweger JP
    Eur Respir J; 2007 Aug; 30(2):321-32. PubMed ID: 17504793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia.
    Mahendradhata Y; Probandari A; Ahmad RA; Utarini A; Trisnantoro L; Lindholm L; van der Werf MJ; Kimerling M; Boelaert M; Johns B; Van der Stuyft P
    Am J Trop Med Hyg; 2010 Jun; 82(6):1131-9. PubMed ID: 20519613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mycobacterium tuberculosis in Taiwan.
    Hsueh PR; Liu YC; So J; Liu CY; Yang PC; Luh KT
    J Infect; 2006 Feb; 52(2):77-85. PubMed ID: 16216328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
    Perlman DC; Gourevitch MN; Trinh C; Salomon N; Horn L; Des Jarlais DC
    J Urban Health; 2001 Sep; 78(3):550-67. PubMed ID: 11564856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
    BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness analysis of strategies for tuberculosis control in developing countries.
    Baltussen R; Floyd K; Dye C
    BMJ; 2005 Dec; 331(7529):1364. PubMed ID: 16282379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
    de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
    Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
    Sweeney S; Berry C; Kazounis E; Motta I; Vassall A; Dodd M; Fielding K; Nyang'wa BT
    PLOS Glob Public Health; 2022; 2(12):e0001337. PubMed ID: 36962909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.
    Diel R; Nienhaus A; Loddenkemper R
    Chest; 2007 May; 131(5):1424-34. PubMed ID: 17494792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective.
    Bell JC; Rose DN; Sacks HS
    AIDS; 1999 Aug; 13(12):1549-56. PubMed ID: 10465080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.
    Tan MC; Marra CA; Sadatsafavi M; Marra F; Morán-Mendoza O; Moadebi S; Elwood RK; FitzGerald JM
    Value Health; 2008; 11(5):842-52. PubMed ID: 18489519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strengthening tuberculosis control overseas: who benefits?
    Nguyen HT; Hickson RI; Kompas T; Mercer GN; Lokuge KM
    Value Health; 2015 Mar; 18(2):180-8. PubMed ID: 25773553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.